EGFR and non-small cell lung carcinoma: Considering that EGFR‐TKIs have little efficacy in patients harboring EGFR 20 insertion (20 ins) mutation, in our present study, 139 NSCLC patients harboring uncommon EGFR mutation excluding EGFR 20 ins mutation were enrolled.